Annual report

Period2024-04-01 → 2025-03-31
Filed2025-06-23
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
MetricValuePeriodScopeSource row
Revenue¥1.04T2024-04-01 → 2025-03-31Cons.Revenue IFRS
Revenue¥921.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥703.3bn2021-04-01 → 2022-03-31dCons.Revenue IFRS (5-year summary)
Revenue¥613.8bn2020-04-01 → 2021-03-31dCons.Revenue IFRS (5-year summary)
Operating income¥157.7bn2024-04-01 → 2025-03-31Cons.Operating profit loss IFRS
Operating income¥140.1bn2023-04-01 → 2024-03-31Cons.Operating profit loss IFRS
Profit before tax¥154.6bn2024-04-01 → 2025-03-31Cons.Profit loss before tax IFRS
Profit before tax¥140.8bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥114.5bn2021-04-01 → 2022-03-31dCons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥97.1bn2020-04-01 → 2021-03-31dCons.Profit loss before tax IFRS (5-year summary)
Net income (owners)¥117.0bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥106.4bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥77.3bn2020-04-01 → 2021-03-31dCons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income¥117.0bn2024-04-01 → 2025-03-31Cons.Profit loss IFRS
Net income¥106.4bn2023-04-01 → 2024-03-31Cons.Profit loss IFRS
Total assets¥1.83Tat 2025-03-31Cons.Assets IFRS
Total assets¥1.83Tat 2024-03-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.47Tat 2022-03-31dCons.Total assets IFRS (5-year summary)
Total assets¥1.35Tat 2021-03-31dCons.Total assets IFRS (5-year summary)
Total liabilities¥459.9bnat 2025-03-31Cons.Liabilities IFRS
Total liabilities¥504.3bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥1.37Tat 2025-03-31Cons.Equity IFRS
Net assets / equity¥1.33Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31dCons.Equity IFRS
Equity (owners)¥1.37Tat 2025-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.33Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥1.01Tat 2022-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥856.7bnat 2021-03-31dCons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥221.9bnat 2025-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥204.9bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS (5-year summary)
Operating cash flow¥210.8bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥146.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥121.5bn2020-04-01 → 2021-03-31dCons.Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow−¥82.5bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥81.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥85.3bn2020-04-01 → 2021-03-31dCons.Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow−¥108.8bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥62.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥7.4bn2020-04-01 → 2021-03-31dCons.Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)¥79.012024-04-01 → 2025-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥71.52023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥59.52022-04-01 → 2023-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥58.722021-04-01 → 2022-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥51.162020-04-01 → 2021-03-31dCons.Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)¥78.992024-04-01 → 2025-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥71.472023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥59.482022-04-01 → 2023-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥58.692021-04-01 → 2022-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥51.052020-04-01 → 2021-03-31dCons.Diluted earnings loss per share IFRS (5-year summary)
Net assets per share¥927.85at 2025-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥893.8at 2024-03-31Cons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥746.07at 2023-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥669.23at 2022-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Net assets per share¥566.57at 2021-03-31dCons.Equity to asset ratio IFRS (5-year summary)
Equity ratio74.8%at 2025-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.5%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio63.4%at 2021-03-31dCons.Ratio of owners equity to gross assets IFRS (5-year summary)
ROE8.7%2024-04-01 → 2025-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.7%2023-04-01 → 2024-03-31Cons.Rate of return on equity IFRS (5-year summary)
ROE8.4%2022-04-01 → 2023-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE9.5%2021-04-01 → 2022-03-31dCons.Rate of return on equity IFRS (5-year summary)
ROE9.6%2020-04-01 → 2021-03-31dCons.Rate of return on equity IFRS (5-year summary)
Employees30,689at 2025-03-31Cons.Number of employees
Employees30,591at 2024-03-31Cons.Number of employees
Employees30,207at 2023-03-31dCons.Number of employees
Employees28,294at 2022-03-31dCons.Number of employees
Employees26,482at 2021-03-31dCons.Number of employees
Revenue¥428.7bn2024-04-01 → 2025-03-31StandaloneNet sales
Revenue¥399.8bn2023-04-01 → 2024-03-31StandaloneNet sales
Revenue¥375.0bn2022-04-01 → 2023-03-31dStandaloneNet sales (5-year summary)
Revenue¥341.4bn2021-04-01 → 2022-03-31dStandaloneNet sales (5-year summary)
Revenue¥316.4bn2020-04-01 → 2021-03-31dStandaloneNet sales (5-year summary)
Operating income¥89.4bn2024-04-01 → 2025-03-31StandaloneOperating income
Operating income¥77.0bn2023-04-01 → 2024-03-31StandaloneOperating income
Ordinary income¥147.8bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥110.7bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥91.1bn2022-04-01 → 2023-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥79.4bn2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥65.3bn2020-04-01 → 2021-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥148.3bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Profit before tax¥112.0bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Net income¥122.3bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥87.9bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥79.0bn2022-04-01 → 2023-03-31dStandaloneNet income loss (5-year summary)
Net income¥62.8bn2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Net income¥52.0bn2020-04-01 → 2021-03-31dStandaloneNet income loss (5-year summary)
Total assets¥1.42Tat 2025-03-31StandaloneAssets
Total assets¥1.44Tat 2024-03-31StandaloneAssets
Total assets¥1.33Tat 2023-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.28Tat 2022-03-31dStandaloneTotal assets (5-year summary)
Total assets¥1.26Tat 2021-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥549.7bnat 2025-03-31StandaloneLiabilities
Total liabilities¥623.6bnat 2024-03-31StandaloneLiabilities
Net assets / equity¥870.0bnat 2025-03-31StandaloneNet assets
Net assets / equity¥813.8bnat 2024-03-31StandaloneNet assets
Net assets / equity¥765.6bnat 2023-03-31dStandaloneNet assets
Net assets / equity¥765.4bnat 2022-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥725.2bnat 2021-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥69.8bnat 2025-03-31StandaloneCash and deposits
Cash and deposits¥93.8bnat 2024-03-31StandaloneCash and deposits
EPS (basic)¥82.582024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥59.052023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥52.612022-04-01 → 2023-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥41.522021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥34.442020-04-01 → 2021-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥82.562024-04-01 → 2025-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥59.032023-04-01 → 2024-03-31StandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥52.592022-04-01 → 2023-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥41.492021-04-01 → 2022-03-31dStandaloneDiluted earnings per share (5-year summary)
EPS (diluted)¥34.372020-04-01 → 2021-03-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥262024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥442023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥402022-04-01 → 2023-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥342021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥292020-04-01 → 2021-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥589.54at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥547.68at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥513.67at 2023-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥505.54at 2022-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥479.13at 2021-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio61.2%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio56.6%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio57.4%at 2021-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE14.5%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE11.1%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE10.3%2022-04-01 → 2023-03-31dStandaloneRate of return on equity (5-year summary)
ROE8.4%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
ROE7.4%2020-04-01 → 2021-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued1,480,559,000at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued745,348,000at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued747,682,000at 2023-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued759,521,000at 2021-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees5,633at 2025-03-31StandaloneNumber of employees
Employees5,554at 2024-03-31StandaloneNumber of employees
Employees5,457at 2023-03-31dStandaloneNumber of employees
Employees5,377at 2022-03-31dStandaloneNumber of employees
Employees5,247at 2021-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2024-04-01 → 2025-03-31¥2.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2025-03-31¥298m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥712m
Blood And Cell Technologies Companyreportable segmentcapex2024-04-01 → 2025-03-31¥17.8bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2025-03-316488 pure
Blood And Cell Technologies Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥200.3bn
Blood And Cell Technologies Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥26.5bn
Cardiac And Vascular Companyreportable segmentcapex2024-04-01 → 2025-03-31¥43.6bn
Cardiac And Vascular Companyreportable segmentemployeesat 2025-03-3117155 pure
Cardiac And Vascular Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥624.4bn
Cardiac And Vascular Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥154.7bn
Medical Care Solutions Companyreportable segmentcapex2024-04-01 → 2025-03-31¥18.5bn
Medical Care Solutions Companyreportable segmentemployeesat 2025-03-316069 pure
Medical Care Solutions Companyreportable segmentrevenue external2024-04-01 → 2025-03-31¥211.2bn
Medical Care Solutions Companyreportable segmentsegment profit2024-04-01 → 2025-03-31¥23.0bn
—segment totalcapex2024-04-01 → 2025-03-31¥79.8bn
—segment totalrevenue external2024-04-01 → 2025-03-31¥1.04T
—segment totalsegment profit2024-04-01 → 2025-03-31¥204.2bn
Reconciling Itemsreconcilingcapex2023-04-01 → 2024-03-31¥4.0bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2024-03-31¥248m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥3.2bn
Blood And Cell Technologies Companyreportable segmentcapex2023-04-01 → 2024-03-31¥17.3bn
Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥168.3bn
Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥16.4bn
Cardiac And Vascular Companyreportable segmentcapex2023-04-01 → 2024-03-31¥41.5bn
Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥555.7bn
Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥123.8bn
Medical Care Solutions Companyreportable segmentcapex2023-04-01 → 2024-03-31¥15.6bn
Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2024-03-31¥197.6bn
Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2024-03-31¥19.8bn
—segment totalcapex2023-04-01 → 2024-03-31¥74.4bn
—segment totalrevenue external2023-04-01 → 2024-03-31¥921.6bn
—segment totalsegment profit2023-04-01 → 2024-03-31¥160.0bn
Blood And Cell Technologies Companyreportable segmentemployeesat 2025-03-31271 pure
Cardiac And Vascular Companyreportable segmentemployeesat 2025-03-312057 pure
Medical Care Solutions Companyreportable segmentemployeesat 2025-03-312426 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,899
ItemContextValueUnit
Comprehensive income IFRS (5-year summary)Prior1YearDuration258816000000JPY
Comprehensive income IFRS (5-year summary)CurrentYearDuration106802000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior4YearInstant856662000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior3YearInstant1012313000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior2YearInstant1111063000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant1327090000000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentYearInstant1368535000000JPY
Total assets IFRS (5-year summary)Prior4YearInstant1351192000000JPY
Total assets IFRS (5-year summary)Prior3YearInstant1473693000000JPY
Total assets IFRS (5-year summary)Prior2YearInstant1602225000000JPY
Total assets IFRS (5-year summary)Prior1YearInstant1831402000000JPY
Total assets IFRS (5-year summary)CurrentYearInstant1828393000000JPY
Equity to asset ratio IFRS (5-year summary)Prior4YearInstant566.57
Equity to asset ratio IFRS (5-year summary)Prior3YearInstant669.23
Equity to asset ratio IFRS (5-year summary)Prior2YearInstant746.07
Equity to asset ratio IFRS (5-year summary)Prior1YearInstant893.80
Equity to asset ratio IFRS (5-year summary)CurrentYearInstant927.85
Basic earnings loss per share IFRS (5-year summary)Prior4YearDuration51.16
Basic earnings loss per share IFRS (5-year summary)Prior3YearDuration58.72
Basic earnings loss per share IFRS (5-year summary)Prior2YearDuration59.50
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration71.50
Basic earnings loss per share IFRS (5-year summary)CurrentYearDuration79.01
Diluted earnings loss per share IFRS (5-year summary)Prior4YearDuration51.05
Diluted earnings loss per share IFRS (5-year summary)Prior3YearDuration58.69
Diluted earnings loss per share IFRS (5-year summary)Prior2YearDuration59.48
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration71.47
Diluted earnings loss per share IFRS (5-year summary)CurrentYearDuration78.99
Ratio of owners equity to gross assets IFRS (5-year summary)Prior4YearInstant0.634
Ratio of owners equity to gross assets IFRS (5-year summary)Prior3YearInstant0.687
Ratio of owners equity to gross assets IFRS (5-year summary)Prior2YearInstant0.693
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.725
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentYearInstant0.748
Rate of return on equity IFRS (5-year summary)Prior4YearDuration0.096
Rate of return on equity IFRS (5-year summary)Prior3YearDuration0.095
Rate of return on equity IFRS (5-year summary)Prior2YearDuration0.084
Rate of return on equity IFRS (5-year summary)Prior1YearDuration0.087
Rate of return on equity IFRS (5-year summary)CurrentYearDuration0.087
Price earnings ratio IFRS (5-year summary)Prior4YearDuration39.08
Price earnings ratio IFRS (5-year summary)Prior3YearDuration31.71
Price earnings ratio IFRS (5-year summary)Prior2YearDuration30.03
Price earnings ratio IFRS (5-year summary)Prior1YearDuration38.17
Price earnings ratio IFRS (5-year summary)CurrentYearDuration35.40
Cash flows from used in operating activities IFRS (5-year summary)Prior4YearDuration121485000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior3YearDuration141467000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior2YearDuration117536000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration146330000000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYearDuration210802000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior4YearDuration-85317000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior3YearDuration-78454000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior2YearDuration-59121000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identitynon_consolidated 2024-03-31pass rounding
balance sheet identitynon_consolidated 2025-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass